BioWorld

Jan. 11, 2005

View Archived Issues

American Bioscience Gains FDA Approval For Abraxane

Providing new hope for breast cancer patients, Abraxane soon will offer the antitumor benefits, without the toxic solvent side effects, of paclitaxel. (BioWorld Today) Read More

Sanofi-Aventis Paying $50M To Regeneron In VEGF Deal

Read More

Saving Cash, Refocusing, Isis Cuts Work Force By 40 Percent

Read More

Invitrogen Getting Antibodies Via $60M Purchase Of Zymed

Read More

Antisoma Buying Aptamera In £11.5M All-Share Merger

Read More

Other News To Note

Read More

Appointments And Advancements

Read More